What is Minerva Neurosciences, Inc. (NERV)?

Minerva Neurosciences, Inc. (NERV) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of NERV?

The current price of NERV is $2.21. Prices are updated in real time on Stocks360.

What is NERV's price-to-earnings (PE) ratio?

NERV's trailing twelve-month PE ratio is -0.08, based on current price and earnings per share data available on Stocks360.

What is NERV's market capitalization?

NERV's market capitalization is $105,522,105.00, placing it in the small-cap tier.

Minerva Neurosciences, Inc. (NERV)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$2.21

Market Cap

$105.52M

PE (TTM)

-0.08

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.12

Day Range

$2.12 – $2.27

52-wk Range

$2.12 – $8.80

Avg Volume

N/A

Volume

204.25K

Minerva Neurosciences, Inc. (NERV) is a publicly traded company in the Healthcare sector. Latest price: $2.21. Market cap $105.52M. Trailing PE -0.08. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $4.23 2026-10-28 · $2.21 (-47.75%)

Earnings

Most Recent

Aug 7, 2026

EPS $-0.14 vs est. $-0.19

Beat by $0.05

Next Earnings

Nov 4, 2026

EPS estimate $-0.14

Proprietary Signals

Signal snapshot temporarily unavailable.

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.08×
P/S (TTM)	0.00×
P/B	-0.51×
P/FCF (TTM)	-0.01×
EV / EBITDA	-0.21×
EV / Sales	0.00×
Earnings Yield	-382.92%
Free Cash Flow Yield	-17796.54%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$80.87M
Net Income (TTM)	-$404.07M
Free Cash Flow (TTM)	-$18.78B
Net Debt	-$24.65M
Working Capital	$75.77M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	250.02%
Return on Invested Capital	-38.56%